Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF
September 17, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 17, 2001
- Healthcare Reform: 30% Copayment for the Insured to Be Focused on
September 17, 2001
- Thorough Quality Control for Imported Medical Devices Called For by PMSB
September 17, 2001
- Hodanren Opposes Raising the Age Limit to 75 for Elderly Healthcare Services
September 17, 2001
- PMSB Budget Related to Medical Devices Focuses on Quality, Prioritization of Review
September 17, 2001
- 3 New Drugs Including Biapenem Recommended for Approval
September 17, 2001
- Enforcement of US/EC MRA Expected to Be Delayed: FDA Officer
September 17, 2001
- NDA Data Disclosure Procedures Notified
September 17, 2001
- MEDICAL DEVICE NEWS IN BRIEF
September 17, 2001
- JETRO Looks Into Social Security Systems in Major Countries
September 17, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 17, 2001
- REGULATORY NEWS IN BRIEF -1-
September 17, 2001
- Club Atmosphere in Contributing to Industry People: Mr Kodama of Pharma Delegates
September 17, 2001
- REGULATORY NEWS IN BRIEF -2-
September 17, 2001
- We Are Sure to Reach \100 Billion by Boosting Sales of Bonalon, Onealfa: Dr Naruchi of Teijin
September 17, 2001
- Dementia to Affect 10% of Elderly Citizens in 2036: Expert
September 17, 2001
- PhRMA Proposes Actual Transaction Price Reimbursement System
September 17, 2001
- Korosho to Conduct Surveys on Terminal Care in FY2002
September 17, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 17, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…